南加州大型医疗系统老年人RSV疫苗许可后自我报告反应原性研究
结果显示GSK疫苗(含AS01E佐剂)接种者局部和全身反应报告率高于辉瑞疫苗,最常见为注射部位疼痛、疲劳、肌痛和头痛,但绝大多数症状短暂且无需就医,未发现与疫苗接种相关的严重事件。
要点
- GSK疫苗接种后局部和全身反应报告率高于辉瑞疫苗,注射部位疼痛分别为56.5%和14.4%。
- 仅约2%的接种者因疫苗相关症状寻求医疗 care,经病历审查仅0.8%被认为可能与接种相关。
- 同日接种新冠疫苗者报告的反应原性症状高于仅接种RSV疫苗者。
核心结论
- RSV疫苗接种后最常见反应为注射部位疼痛、疲劳、肌痛和头痛,GSK疫苗(含AS01E佐剂)报告率高于辉瑞疫苗。
- 大多数症状短暂且无需医疗 care,未发现与疫苗接种相关的严重事件,与许可前安全性数据一致。
研究设计与样本
- 纳入14482名≥60岁RSV疫苗接种者(GSK 7873人[59%],辉瑞5555人[41%]),其中1054人同日接种新冠疫苗。
- 参与者收到接种后14天调查,自我报告局部和全身反应;对自我报告因疫苗相关症状就医者在接种后21天内进行病历审查。
主要发现
- GSK组和辉瑞组注射部位疼痛报告率分别为56.5%和14.4%,疲劳分别为35.5%和21.8%,肌痛分别为26.2%和13.0%,头痛分别为21.5%和12.8%,发热分别为7.8%和3.3%。
- GSK组158/7873(2.0%)和辉瑞组104/5555(1.9%)报告因疫苗相关症状寻求医疗 care。
- 229人至少有1次接种后0-21天电子健康记录就诊,其中102人(0.8%)被认为可能与疫苗接种相关(GSK 69人,辉瑞33人,RSV+新冠0人)。
- 病历审查中最常见的可能相关诊断为呼吸道症状,如咳嗽(GSK n=20,辉瑞 n=9)和鼻塞(GSK n=13,辉瑞 n=6)。
- 同日接种新冠疫苗者报告的反应原性症状高于仅接种RSV疫苗者。
临床怎么用
- 向老年人接种RSV疫苗时应告知常见反应(注射部位疼痛、疲劳、肌痛、头痛),并说明GSK疫苗反应报告率较高但多为短暂。
- 接种后严重就医事件罕见,可据此安抚接种者,减少不必要的医疗就诊。
- 同日接种新冠疫苗可能增加反应原性症状,接种咨询时可提及。
局限性
- 反应原性数据基于自我报告,可能存在报告偏倚。
- 研究限于南加州大型 integrated healthcare system 的参保老年人,外推性受限。
- 未报告不同年龄、性别或基础疾病亚组的详细分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Digital surveys and electronic health records (EHR) can be combined to provide comprehensive assessments of vaccine safety. Limited post-marketing safety data exists for two new RSV vaccines among older adults (Pfizer RSVPreF and GSK RSVPreF3 + ASO1). METHODS: We used digital survey data from adults ≥60 years receiving RSV vaccines through Kaiser Permanente Southern California from November 8, 2023, to February 29, 2024. Enrolled participants received 14-day post-vaccination surveys soliciting local and systemic reactions. Survey results were combined with EHR data. Medical chart reviews were conducted among participants self-reporting receiving medical care for vaccine-related symptoms within 21 days of vaccination. RESULTS: We recruited 14,482 participants aged ≥60 years following RSV vaccination (GSK: 7873 [59%]; Pfizer: 5555 [41%]), including 1054 participants receiving COVID-19 vaccinations on the same day (GSK:618; Pfizer:436). Local and systemic reactions were reported more frequently following GSK vaccinations than Pfizer. The most frequently reported reactions were pain at injection site (56.5% and 14.4%, respectively), fatigue (35.5% and 21.8%), myalgia (26.2% and 13.0%), headache (21.5% and 12.8%) and fever (7.8% and 3.3%). Participants rarely reported seeking medical care (GSK: 158/7873;2.0%; Pfizer: 104/5555;1.9%). Of these, 229 had ≥1 EHR-documented medical encounter 0-21 days post-vaccination, of which 102 (0.8%) were considered possibly related to vaccination (GSK:69; Pfizer:33; RSV + COVID-19:0). Via chart review, the most common diagnoses identified as possibly related to vaccination included respiratory symptoms, such ascough (n = 20 and n = 9, respectively) and congestion (n = 13 and n = 6). No severe events were deemed related to vaccination. Reported reactogenicity symptoms were higher among participants receiving COVID-19 vaccines on the same day compared to participants receiving RSV vaccines alone. CONCLUSION: The most common reactions after RSV vaccines were local pain, fatigue, myalgia, and headache. GSK vaccine recipients containing the AS01E adjuvant reported reactions more frequently than Pfizer vaccine recipients. Consistent with pre-licensure safety data, most symptoms were transient and did not require medical care.
引用
- Malden DE, Ackerson BK, Gee J, et al. Self-reported reactogenicity of RSV vaccines among older adults: a post-licensure study within a large integrated healthcare system in Southern California. Vaccine. 2026. PMID: 41875692. doi:10.1016/j.vaccine.2026.128493
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。